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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S337Conclusion: PGRN plays a chondroprotective role in the pathogenesis
of OA, through a) inhibiting TNFa-induced catabolic and b) activating
anabolic metabolism as a novel chondrogenic growth factor.
Fig. 3. The protective role of PRGN in surgically-induced osteoarthritis A)
PGRN-/-mice showed elevated degradation of cartilage in DMM model. B)
Intra-articular injection of PRGN reduces the loss of proteoglycan in sur-
gically induced OA.
Figure 1. PGRN effectively prevents the loss of cartilage by TNF-a. Total
RNA was extracted and real-time polymerase chain reaction (PCR) was
performed using a sequence-speciﬁc probe and primers for MMP13 (a),
RUNX2 (b), COX-2 (c) and iNOS (d). Each was tested under three con-
ditions (control, TNF-a and TNF-awith PGRN). Our results demonstrated a
drastic decrease in all metabolic levels with the induction of PGRN (Figure
4.a, b, c, d).
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TNFa IS A CRITICAL MEDIATOR OF SYNOVIAL HYPERPLASIA AND
OSTEOPHYTE FORMATION IN HIGH FAT-FED MICE
R.A. Mooney, D. Hamada, R. Maynard, S.L. Kates, M.J. Zuscik. Univ. of
Rochester Med. Ctr., Rochester, NY, USA
Purpose: Obesity and associated type 2 diabetes are important risk fac-
tors for osteoarthritis (OA). A critical hallmark of themetabolic disease ofdiabetes is a low-grade chronic inﬂammation. Evidence indicates that the
proinﬂammatory cytokine TNFa plays an important role inmediating the
metabolic dysfunction in this state. Inﬂammation is now also recognized
to be a contributing factor in the pathogenesis of osteoarthritis. Here we
use human ﬁbroblast-like synoviocytes (FLS) and mouse models to test
thehypothesis that TNFaplays an important role inmediating theadverse
effects of obesity and type 2 diabetes on two aspects of OA progression:
synovial hyperplasia and osteophyte formation.
Methods: Animals: Male C57BL/6J (wild type) mice were bred from
existing colonies and age matched to TNFa-/- mice (Jackson Labs). Mice
were placed on high-fat (HF, 60% kcal, D12492) or low-fat (LF, 10% kcal,
D12450B) diets at 5 weeks of age (Open Source Diets, Research Diets).
Mice were continued on their diets for 24 weeks before sacriﬁce and
harvest. Histology: Following sacriﬁce, knee joints were isolated and
formalin ﬁxed, decalciﬁed, and embedded in parafﬁn. Sagittal sections
were stained with Alcian blue-hematoxylin before assessment. Synovial
samples: Human FLSs were isolated from the synovial tissues of OA
patients undergoing total knee arthroplasty. FLSs were serum-starved
overnight prior to 24h treatment with cytokine and insulin. Total RNA
was extracted from FLSs and gene expression quantitated by qRT-PCR.
Results: Immunohistochemistry demonstrated that while TNFa and
BMP2 were not detected in the synovium of LF fed mice, there was
strong synovial expression of both genes in mice fed the HF diet. This
increased expression was associated with synovial hyperplasia and
increased formation of osteophytes. To investigate these potential
mediators of HF diet-associated osteoarthritis more directly, the
response of human FLSs to TNFa was examined. In response to TNFa
treatment, expression of BMP2 and TNFa was increased 6 and 40-fold,
respectively, as measured by qRT-PCR. The latter result suggests a feed
forward ampliﬁcation of TNFa. Importantly, insulin inhibited the effects
of TNFa on BMP2 expression by approximately 50%. To assess the in vivo
effect of TNFa, TNFa knockout mice were placed on the HF and LF diets
for 24weeks. As expected, absence of TNFa blunted theweight gain and
the glucose intolerance that is observed in HF diet fed mice. In LF fed
TNFa-/- mice, osteophyte numbers and synovial hyperplasia were
modestly increased above baseline, suggesting a role for TNFa in joint
maintenance under control conditions. Importantly, the increase in
osteophyte number and synovial hyperplasia present in HF-fed wild
type mice was completely absent in HF TNFa-/- mice, supporting a
pathogenic role for TNFa in osteoarthritis during HF diet consumption,
obesity, and type 2 diabetes/systemic inﬂammation.
Conclusions: TNFa plays an important role in the weight gain and
metabolic dysregulation of HF diet-associated obesity and type 2 dia-
betes. TNFa also promotes expression of osteoarthritis-associated
cytokines by FLSs, which can be reversed by insulin treatment, sug-
gesting a protective role for insulin in synovial joints. Finally, the
TNFa-/- mouse model conﬁrms the critical role of TNFa in the patho-
genesis of synovial hyperplasia and osteophyte formation in HF-fed,
obese and diabetic mice.
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SHORT BUT NOT LONG TERM SCLEROSTIN INHIBITION WORSENS
POST-TRAUMATIC OSTEOARTHRITIS IN MICE
B.Y. Chan, S. Zaki, S. Smith, M. Smith, C.B. Little. Raymond Purves Res.
Labs, Kolling Inst. of Med. Res., The Univ. of Sydney, St Leonards, Australia
Purpose: Sclerostin (SOST) and dikkopf-1 (DKK1) are secreted proteins
that inhibitWnt signaling. IncreasedWnt-b-catenin activity is implicated
in cartilage degradation in osteoarthritis (OA), at the same time driving
increased bone formation (subchondral thickening, osteophytes) that
typiﬁes OA. This suggests that increasing SOST/DKK1 may be protective
while inhibiting these Wnt antagonists may worsen OA cartilage and
bone pathology. A recent report found that over-expression of DKK1 in
chondrocytes did indeed reduce cartilage and bone pathology in post-
traumatic (pt)OA in mice, however in another study systemic SOST
inhibition did not alter ptOA cartilage erosion in rats. Whether these
different outcomes relate to the inhibitor targeted and their systemic
versus cell-speciﬁc regulation, or the species and ptOA model used is
unclear. The present study examined whether systemic inhibition of
SOST changed ptOA pathology in mice induced by the same meniscal
destabilization (DMM) model as in the DKK1 over-expression study.
Methods: Forty-eight 10-week male C57BL6 mice had unilateral DMM
surgery andwere randomly assigned to receive 20mg/kg of anti-SOSTor
control IgG antibody (provided by Eli-Lilly) subcutaneously twice
weekly: from the day of surgery and sacriﬁced at 4 (group 1) or 8 (group
